

Emergent BioSolutions to Release Second Quarter 2011 Financial Results and Conduct a Conference Call on August 4, 2011

July 11, 2011 7:01 AM ET

ROCKVILLE, Md., Jul 11, 2011 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the second quarter 2011 on Thursday, August 4, 2011, after market close.

Company management will host a conference call at 5:00 pm Eastern on August 4, 2011 to discuss the financial results for the second quarter and first six months of 2011, recent business developments, revenue guidance for the third quarter of 2011 and revenue and net income guidance for full year 2011. The conference call will be accessible by dialing **888/713-4214** or **617/213-4866** (international) and providing passcode **23117164**. A webcast of the conference call will be accessible from the company's website at <http://www.emergentbiosolutions.com>, under "Investors".

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website: <http://www.theconferencingservice.com/prereg/key.process?key=PXNXANWPF>.

A replay of the conference call will be accessible, approximately two hours following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using passcode 93267041. The replay will be available through August 18, 2011. The webcast will be archived on the company's website, <http://www.emergentbiosolutions.com>, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent's marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at <http://www.emergentbiosolutions.com>.

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

Investors Contact:

Robert G. Burrows
Vice President, Investor Relations
301-795-1877

BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt
Vice President, Corporate Communications
301-795-1800

SchmittT@ebsi.com